DOCSLIB.ORG

Multiomyx™ Panel Brochure

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Multiomyx™ Panel Brochure Verified MultiOmyx™ Multiplexing Panels Immune Panel (TIL panel) – 12 markers Tested in multiple cancer indications (melanoma, lung, colorectal, prostate, breast) TIL Panel Co-expression Phenotypes CD3 CD3+CD4+ T helper CD4 CD3+CD4+FoxP3+ T regulatory CD8 CD3+CD4+CD45RO+ Memory T helper CD45RO CD3+CD4+PD1+ Immune modulation FoxP3 CD3+CD8+ T cytotoxic CD20 CD3+CD8+CD45RO+ Memory T cytotoxic CD68 CD3+CD8+PD1+ Immune modulation CD56 CD68+ Macrophage PanCK+ CD8+ PD-L1+ CD68+ FoxP3+ Au Q. et al. (April, 2016). MultiOmyx™ multiplexed tumor infiltrating lymphocyte CTLA-4 CD68+PDL1+ Macrophage PD-L1 panel provides comprehensive immunophenotyping from a single FFPE slide. Poster presented at AACR Annual Meeting, New Orleans, LA. PD-1 CD20+ B cell PD-L1 CD20+PDL1+ B cell PD-L1 PanCK CD3-CD56+ Natural Killer cell PanCK+PDL1+ Tumor cell PD-L1 Myeloid Panel – 10 markers Tested in PDAC tissue Myeloid Panel Co-expression Phenotypes CD11b CD11b+CD33+ Myeloid cells M1 TAM CD14 CD11b+CD33+HLADR- MDSC CD15 CD11b+CD33+HLADR-CD14+CD15- M-MDSC CD16 CD11b+CD33+HLADR-CD14-CD15+ G-MDSC CD33 CD68+ TAM CD68 CD68+HLADR+CD163- M1 TAM CD163 CD68+HLADR-CD163+ M2 TAM HLA-DR CD11b+HLADR-CD16+ Neutrophil/G-MDSC PanCK+ CD68+ CD11b+ HLA-DR+ Juncker-Jensen A. et al. (April, 2018). Tumor-Infiltrating Myeloid Cells – Using Arginase1 MultiOmyx™ to Distinguish between MDSCs, TAMs and TANs in the Pancreatic Tumor Microenvironment. Poster presented at AACR Annual Meeting, Chicago, IL. PanCK Verified MultiOmyx™ Multiplexing Panels TIL & Myeloid Panel #1 – 16 markers Tested in NSCLC tissue TIL/TAM Panel #1 Co-expression Phenotypes CD3 CD3+CD4+ T helper LAG3+/PD1+ CTL CD4 CD3+CD4+FoxP3+ T regulatory CD8 CD3+CD4+PD1+ Immune modulation FoxP3 CD3+CD8+ T cytotoxic CD20 CD8+PD1+ Immune modulation CD68 CD3+TIM3+ Immune modulation CD163 CD3+LAG3+ Immune modulation CD11b CD3+ICOS+ Immune modulation PanCK+ LAG-3+ PD-1+ CD8+ Juncker-Jensen A. et al. (2019, December). PD-1 and LAG-3 synergize to drive CD15 CD3+OX40+ Immune modulation tumor-infiltration of T cytotoxic cells in NSCLC tumors. Poster presented at ESMO I/O Annual Meeting, Geneva, Switzerland. TIM-3 CD20+ B cell LAG-3 CD11b+CD15+ Granulocyte OX40 CD68+ TAM ICOS CD68+CD163+ M2 TAM PD-1 CD68+PDL1+ Macrophage PD-L1 PD-L1 CD68+TIM3+ Macrophage TIM-3 PanCK PanCK+PDL1+ Tumor cell PD-L1 TIL & Myeloid Panel #2 – 19 markers Tested in PDAC tissue TIL/Myeloid Panel Co-expression Phenotypes #2 CD3+CD4+ T helper CD3 CD3+CD4+FoxP3+ T regulatory G-MDSC CD4 CD3+CD4+PD1+ Immune modulation CD8 CD3+CD8+ T cytotoxic CD45RO CD8+PD1+ Immune modulation FoxP3 CD8+GranzymeB+ Effector T cytotoxic CD11b CD3+CD45RO Memory T cells CD14 CD68+ TAM PanCK+ CD11b+ CD3+ CD15+ FoxP3+ ™ CD15 Juncker-Jensen A. et al. (October, 2018). Using MultiOmyx to Analyze CD68+HLADR+CD163- M1 TAM Correlations between Immunosuppressive Cells and Tumor-Infiltrating CD16 Lymphocytes in the Pancreatic Tumor Microenvironment. Poster presented at CD68+HLADR-CD163+ M2 TAM ESMO Annual Meeting, Munich, Germany. CD33 CD68+PDL1+ Macrophage PD-L1 CD68 CD11b+CD33+ Myeloid cells CD163 CD11b+CD33+HLADR- MDSC HLA-DR CD11b+CD33+HLADR-CD14+CD15- M-MDSC Arginase1 CD11b+CD33+HLADR-CD14-CD15+ G-MDSC GranzymeB PanCK+Ki67+ Proliferating tumor Ki67 PanCK+PDL1+ Tumor cell PD-L1 PD-1 PD-L1 PanCK 2 | Verified MultiOmyx™ Multiplexing Panels Dendritic Cell Panel – 15 markers Tested in melanoma tissue Dendritic Panel Co-expression Phenotypes CD3 CD3+CD4+ T helper pDC CD4 CD3+CD8+ T cytotoxic CD8 CD68+ TAM CD11c CD68+HLADR+CD163- M1 TAM CD14 CD68+HLADR-CD163+ M2 TAM CD40 CD123+HLADR+ pDC CD68 CD123+HLADR+CD40+ CD40 positive pDC CD123 CD123+HLADR+DCLAMP+ Activated pDC CD141 CD11c+Clec9A+CD141+HLADR+ cDC CD163 CD11c+Clec9A+CD141+CD40+ CD40 positive cDC SOX10+CD123+HLADR+CD11c+ Gozo M. et al. (2020, June). Distinguishing dendritic cell subtypes in the HLA-DR CD11c+Clec9A+CD141+DCLAMP+ Activated cDC tumor microenvironment using MultiOmyxTM. Poster presented at AACR Annual Meeting, Virtual. Clec9A CD11c+CD14+DCSIGN+HLADR+ Monocyte derived DC DC-SIGN DC-LAMP SOX10/PanCK Tertiary Lymphoid Structure (TLS) Panel – 14 markers Tested in bladder cancer tissue TLS Panel Co-expression Phenotypes CD3 CD3+CD4+ T helper CD4 CD3+CD4+FoxP3+ T regulatory CD8 CD3+CD8+ T cytotoxic FoxP3 CD20+ B cell CD11b CD11b+HLADR+ APC myeloid cell CD14 CD11b+HLADR- MDSC CD15 CD11b+HLADR-CXCR2+ MDSC positive for CXCR2 CD20 CD11b+HLADR-iNOS MDSC positive for iNOS CD68 CD11b+HLADR-CD14+CD15- M-MDSC HEV PNAd CD11b+HLADR-CD14+CD15- G-MDSC CXCR2 CD68+ TAM iNOS CD68+HLADR+ M1 TAM CD20+ PNAd+ CD3+ Image of TLS in a bladder cancer sample from an unpublished academic HLA-DR CD68+iNOS+ M1 TAM collaboration study with University of Notre Dame. PanCK PNAd+ High Endothelial Venule PanCK+iNOS+ iNOS positive tumor cells Verified MultiOmyx™ Multiplexing Panels | 3 TIL, TAM & Vessel Panel #1 – 10 markers Tested in breast cancer tissue TIL/TAM Panel #1 Co-expression Phenotypes CD3 CD3+CD4+ T helper CD4 CD3+CD4+FoxP3+ T regulatory CD8 CD3+CD8+ T cytotoxic FoxP3 CD68+ TAM CD68 CD68+HLADR+CD163- M1 TAM CD163 CD68+HLADR-CD163+ M2 TAM PanCK+ CD3+ CD34+ Ki67+ HLA-DR CD34+ Vessels Juncker-Jensen A. et al. (April, 2019). Pro-Tumorigenic Mechanisms of M2 Tumor- Associated Macrophages in Triple-Negative Breast Cancer. Poster presented at Ki67 PanCK+Ki67+ Proliferating tumor AACR Annual Meeting, Chicago, IL. CD34 PanCK TIL, TAM & Vessel Panel #2 – 16 markers Tested in ovarian tumor tissue TIL/TAM Panel #2 Co-expression Phenotypes M1 TAM CD3 CD3+CD4+ T helper CD4 CD3+CD4+FoxP3+ T regulatory M2 TAM CD8 CD3+CD4+PD1+ Immune modulation FoxP3 CD4+CTLA4+ Immune modulation CD20 CD3+CD8+ T cytotoxic CD68 CD8+PD1+ Immune modulation CD163 CD8+CTLA4+ Immune modulation HLA-DR CD20+ B cell S100+ CD68+ HLA-DR+ CD163+ PD-1 CD68+ TAM Juncker-Jensen A. et al. (2019, October). An Integrated Multiplexing Approach for the Immunoprofiling of the Tumor Microenvironment of Ovarian Granulosa Cell PD-L1 CD68+HLADR+CD163- M1 TAM Tumors. Poster presented at AACR-NCI-EORTC Annual Meeting, Boston, MA. CTLA-4 CD68+HLADR-CD163+ M2 TAM CD34 CD68+PDL1+ Macrophage PD-L1 Vimentin CD34+ Vessels S100 PanCK+Ki67+ Proliferating tumor Ki67 PanCK+PDL1+ Tumor cell PD-L1 PanCK 4 | Verified MultiOmyx™ Multiplexing Panels TIGIT Immune Cell Panel – 15 markers Tested in NSCLC & melanoma tissue TIGIT Immune Panel Co-expression Phenotypes TIGIT CD3+CD4+ T helper CD226 CD3+CD4+FoxP3+ T regulatory CD155 CD3+CD4+PD1+ Immune modulation CD3 CD3+CD8+ T cytotoxic CD4 CD8+PD1+ Immune modulation CD8 CD8+GranzymeB+ Effector T cytotoxic FoxP3 CD68+ TAM SOX10 + TIGIT+ LAG3+ PD1+ Au Q. et al. (April, 2019). Characterization of TIGIT Expression Using MultiOmyx™ Hyperplexed Immunofluorescence Assay in NSCLC and melanoma. CD56 CD68+HLADR+CD163- M1 TAM Poster presented at AACR Annual Meeting, Atlanta, GA. CD45RO CD68+HLADR-CD163+ M2 TAM CD11b CD68+PDL1+ Macrophage PD-L1 CD11c CD11b+CD33+ Myeloid cells PD-1 CD11b+CD33+HLADR- MDSC LAG-3 CD11b+CD33+HLADR-CD14+CD15- M-MDSC TIM-3 CD11b+CD33+HLADR-CD14-CD15+ G-MDSC PanCK/SOX10 PanCK+Ki67+ Proliferating tumor PanCK+PD1+ Tumor cell PD-L1 Myeloid Leukemia Immune Panel – 14 markers Tested in AML/HL/DLBCL Leukemia Panel Co-expression Phenotypes CD3 CD3+CD4+ T helper G-MDSC CD4 CD3+CD4+FoxP3+ T regulatory CD8 CD3+CD8+ T cytotoxic G-MDSC FoxP3 CD68+ TAM G-MDSC CD68 CD68+HLADR+CD163- M1 TAM CD163 CD68+HLADR-CD163+ M2 TAM HLA-DR CD11b+CD33+ Myeloid cells CD11b CD11b+CD33+HLADR- MDSC CD11b+CD33+CD15+CD34+ Au Q. et al. (2019, December). Phenotypic Characterization of the Immune CD33 CD11b+CD33+HLADR-CD14+CD15- M-MDSC Landscape in the Bone Marrow of Patients with Acute Myeloid Leukemia (AML) Using MultiOmyx™ Hyperplexed Immunofluorescence CD14 CD11b+CD33+HLADR-CD14-CD15+ G-MDSC Assay. Poster presented at ASH Annual Meeting, Orlando, FL. CD15 CD11b+CD33+HLADR-CD14-CD15+Arg1 Arg1+ G-MDSC CD34 Arginase1 Tumor marker Verified MultiOmyx™ Multiplexing Panels | 5 Hepatitis B (HBV) Panel – 19 markers Tested in liver tissue HBV Panel Co-expression Phenotypes HBcAG CD3+CD4+ T helper HBsAG CD3+CD4+FoxP3+ T regulatory NaKATPase CD3+CD4+PD1+ Immune modulation CD3 CD3+CD8+ T cytotoxic CD4 CD3+CD8+PD1+ Immune modulation CD8 CD68+ TAM FoxP3 CD68+HLADR+ M1 macrophage CD56 CD68+CD163+ M2 macrophage HBcAG+ HBsAG+ DAPI+ CD20 CD68+PDL1+ Macrophage PD-L1 CD11b CD68+DCSIGN+ Macrophage DC-SIGN HLA-DR CD11b+HLADR- MDSC CD11c CD11c+HLADR+ Dendritic cell (cDC) DC-SIGN CD11c+HLADR+DCSIGN+ Dendritic cell CD68 CD20+ B cell Dendritic cell CD163 CD20+HLADR+ B cell HLA-DR PD-1 CD56+CD3- NK cell PD-L1 CD56+CD3-HLADR+ NK cell HLA-DR CD11c+ HLADR+ CD68+ CD20+ IDO1 Ki67 NASH Liver Panel – 17 markers Tested in liver tissue NASH Panel Co-expression Phenotypes CD11b CD11b+CD11c+CD14-HLADR+ cDC HLA-DR CD11c+HLADR+CD14-IDO1+ cDC IDO1+ CD68 CD11b+CD11c+HLADR+CD14-Ki67+ cDC proliferating CD163 CD68+CD163+CD16 Kupffer cell Kupffer cell CD11c CD68+CD163+CD16+DCSIGN+ Kupffer cell DC-SIGN+ DC-SIGN CD68+CD163+CD16+PDL1+ Kupffer cell PD-L1+ CD66b Kupffer cell prolifer- CD68+CD163+CD16+Ki67+ ating CD9 CD68+ CD16+ CD163+ CD68+CD163+CD16+CD33+ Kupffer cell CD33+ CD14 CD11b+CD14+HLADR+ Tmo CD16 CD11b+CD14+HLADR+CD16+ TMo CD16+ CD33 HLADR+CD9+CD14+ SAM SMA HLADR+CD9+CD14+TREM2+ SAM TREM2+ TREM2 HLADR+CD9+CD14+PDL1+ SAM PD-L1+ MNDA HLADR+CD9+CD14+DCSIGN+ SAM DC-SIGN+ IDO1 HLADR+CD9+CD14+CD33+ SAM CD33+ PD-L1 HLADR+CD9+CD14+MNDA+ SAM MNDA+ Ki67 HLADR+ CD16+ CD14+ CD9+ HLADR+CD9+CD14+Ki67+ SAM proliferating PD-L1 PanCK 6 | Verified MultiOmyx™ Multiplexing Panels Verified MultiOmyx™ Multiplexing Panels | 7 About NeoGenomics NeoGenomics is an industry-leading cancer diagnostics and pharma services company.
Load more

Recommended publications
  • Serum Scd163 As a Biomarker of Adipose Tissue Inflammation in Obstructive Sleep Apnoea Patients: Limits and Perspectives
    AGORA | CORRESPONDENCE Serum sCD163 as a biomarker of adipose tissue inflammation in obstructive sleep apnoea patients: limits and perspectives To the Editor: Recently, MURPHY et al. [1] demonstrated, through a challenging animal, cellular and human translational approach, that intermittent hypoxia induces a pro-inflammatory activation of adipose tissue macrophages (ATMs), promoting insulin resistance. They confirmed that intermittent hypoxia lowers insulin-mediated glucose uptake in 3T3-L1 adipocytes, and evidenced the interrelationship between inflammation and insulin resistance in the adipose tissue of mice exposed to intermittent hypoxia. They then measured the concentration of serum soluble CD163 (sCD163), an assumed pro-inflammatory biomarker reflecting macrophage activation, in obstructive sleep apnoea (OSA) patients classified according to their BMI and apnoea/hypopnoea index (AHI). This is the first time serum sCD163 has been evaluated in OSA patients, and its association with AHI is promising. With the aim of enhancing its relevance in further studies, we wish to discuss the following points. 1) Activation of adipose tissue macrophages (ATMs) towards M1 phenotype in OSA patients. MURPHY et al. [1] made the assumption that circulating sCD163 levels in OSA patients reflect the intermittent hypoxia-dependent polarisation of ATMs towards a M1 phenotype. As appropriately cited, KRAČMEROVÁ et al. [2] showed that circulating sCD163 concentrations are associated with both macrophage content in human adipose tissue, and insulin sensitivity. However, the assumption that serum sCD163 reflects such a polarisation based on the ADAM-17-dependent cleavage, as hypothesised by ETZERODT et al. [3], is unconvincing since only shown in HEK293 cells. Human ATMs are characterised by a high expression of CD163 which, in contrast, is weakly expressed in differentiated M1 macrophages [4].
    [Show full text]
  • IL-7 Receptor Blockade Blunts Antigen-Specific Memory T Cell
    ARTICLE DOI: 10.1038/s41467-018-06804-y OPEN IL-7 receptor blockade blunts antigen-specific memory T cell responses and chronic inflammation in primates Lyssia Belarif1,2, Caroline Mary1,2, Lola Jacquemont1, Hoa Le Mai1, Richard Danger1, Jeremy Hervouet1, David Minault1, Virginie Thepenier1,2, Veronique Nerrière-Daguin1, Elisabeth Nguyen1, Sabrina Pengam1,2, Eric Largy3,4, Arnaud Delobel3, Bernard Martinet1, Stéphanie Le Bas-Bernardet1,5, Sophie Brouard1,5, Jean-Paul Soulillou1, Nicolas Degauque 1,5, Gilles Blancho1,5, Bernard Vanhove1,2 & Nicolas Poirier1,2 1234567890():,; Targeting the expansion of pathogenic memory immune cells is a promising therapeutic strategy to prevent chronic autoimmune attacks. Here we investigate the therapeutic efficacy and mechanism of new anti-human IL-7Rα monoclonal antibodies (mAb) in non-human primates and show that, depending on the target epitope, a single injection of antagonistic anti-IL-7Rα mAbs induces a long-term control of skin inflammation despite repeated antigen challenges in presensitized monkeys. No modification in T cell numbers, phenotype, function or metabolism is observed in the peripheral blood or in response to polyclonal stimulation ex vivo. However, long-term in vivo hyporesponsiveness is associated with a significant decrease in the frequency of antigen-specific T cells producing IFN-γ upon antigen resti- mulation ex vivo. These findings indicate that chronic antigen-specific memory T cell responses can be controlled by anti-IL-7Rα mAbs, promoting and maintaining remission in T- cell mediated chronic inflammatory diseases. 1 Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, INSERM, Université de Nantes, Nantes 44093, France. 2 OSE Immunotherapeutics, Nantes 44200, France.
    [Show full text]
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • AML Serum Mir-150 Mir-155 Mir-1246 Prog
    Supplementary Table S1. Summary of current studies on EVs as biomarkers Disease Source Cargo Role Reference AML serum TGF-β1, CD34, Prognostic [21] CD33, CD117 AML serum miR-150 Prognostic [23] miR-155 miR-1246 AML serum miR-125b Prognostic [24] AML serum miR-10b Prognostic [25] CLL serum CD19, CD37 Prognostic [27] CLL plasma S100-A9 protein Prognostic [29] CLL plasma CD52 Prognostic [30] CLL plasma miR-150, miR-155, Diagnostic [31] miR-223, miR-29 CD37, CD9, CD63 CLL plasma mc-COX2 Prognostic [33] MF plasma CD61, CD62P Prognostic [34] MM serum CD38, CD138, Prognostic [37] CD44, CD147 MM serum let-7b and miR-18a Prognostic [40] nHL /HL plasma CD20/CD30 Diagnostic/Prognostic [20] Lymphoma plasma CD20 Prognostic [43] HL plasma miR-23p Diagnostic [44] miR-127-3p miR-21-5p miR-155-5p let-7a-5p Lymphoma plasma BCL-6 Prognostic [45] c-myc 1 Supplementary Table S2. Summary of current studies on EVs: re-education of the bone marrow niche Disease EV Target Cargo Functional effects Reference origin/Source AML AML cells MSC/stromal / Downregulating of KITL, [52] cells CXCL12, IGF1; Reducing support to normal hemopoiesis AML AML cells Stromal cells miR-155 Reducing secretion of [54] miR-375 cytokines and growth factor; miR-150 Affecting retention and differentiation of HSC in the bone marrow AML/MDS AML/MDS cells MSC miR-7977 Reducing the hemopoiesis [55] supportive capacity CLL CLL cells MSC miR-202-3p Promoting migration, [32] survival and proliferation CLL Plasma Stromal cells / Production of VEGF, [26] promoting survival of B cells CLL CLL cells
    [Show full text]
  • The Role of Tumor Necrosis Factor-Like Weak Inducer of Apoptosis in Atherosclerosis Via Its Two Different Receptors (Review)
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 14: 891-897, 2017 The role of tumor necrosis factor-like weak inducer of apoptosis in atherosclerosis via its two different receptors (Review) HENGDAO LIU1,2, DAN LIN3, HONG XIANG1, WEI CHEN1, SHAOLI ZHAO1,4, HUI PENG1, JIE YANG1, PAN CHEN1, SHUHUA CHEN1 and HONGWEI LU1,2 1Center for Experimental Medical Research; 2Department of Cardiology, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013; 3Qingdao Center for Disease Control and Prevention, Qingdao, Shandong 266033; 4Department of Endocrinology, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China Received May 3, 2016; Accepted March 31, 2017 DOI: 10.3892/etm.2017.4600 Abstract. At present, it is commonly accepted that athero- 1. Introduction sclerosis is a chronic inflammatory disease characterized by disorder of the arterial wall. As one of the inflammatory cyto- Atherosclerosis remains a major global challenge (1). The kines of the tumor necrosis factor superfamily, tumor necrosis World Health Organization statistics data suggest that, by factor-like weak inducer of apoptosis (TWEAK) participates 2020, atherosclerosis will be the most common cause of death in the formation and progression of atherosclerosis. TWEAK, and morbidity in both developed and developing countries (2). when binding to its initial receptor, fibroblast growth factor Atherosclerosis has long been studied as a chronic inflamma- inducible molecule 14 (Fn14), exerts adverse biological func- tory disorder of the arterial wall, which involves numerous tions in atherosclerosis, including dysfunction of endothelial cytokines. Accumulating data suggests that one of the cyto- cells, phenotypic change of smooth muscle cells and inflam- kines, tumor necrosis factor-like weak inducer of apoptosis matory responses of monocytes/macrophages.
    [Show full text]
  • Immunocytochemical Analysis of Human Synovial Lining Cells: Phenotypic Relation to Other Marrow Ann Rheum Dis: First Published As 10.1136/Ard.50.5.311 on 1 May 1991
    Annals ofthe Rheumatic Diseases 1991; 50: 311-315 31 Immunocytochemical analysis of human synovial lining cells: phenotypic relation to other marrow Ann Rheum Dis: first published as 10.1136/ard.50.5.311 on 1 May 1991. Downloaded from derived cells N A Athanasou, J Quinn Abstract system,20 21 synovial lining cell specific The antigenic phenotype of human synovial progenitors are produced in the marrow by a lining cells in normal and hyperplastic synovial lining cell lineage that diverges at some synovium intima was determined with a panel early stage from that of monocytes and tissue of monoclonal antibodies directed against macrophages. a large number of well defined myeloid To investigate the origin and development of (macrophage/granulocyte associated) antigens. synovial lining cells further we sought to define Synovial lining cells express numerous macro- the antigenic phenotype of human synovial phage associated antigens, including CD11b lining cells and subintimal macrophages in the (CR3), CD13, CD14, CD16 (FcRIII), CD18, synovial membrane. We used a large number of CD32 (FcRII), CD45 (leucocyte common monoclonal antibodies directed against defined antigen), CD54 (ICAM-1), CD64 (FcRI), myeloid (granulocyte/macrophage associated) CD68, and CD71 (transferrin receptor). antigens for the immunohistochemical staining Few synovial lining cells expressed CD11a of human synovial lining cells and subintimal (LFA-1) and CD11c (p150,95). Subintimal macrophages in the synovial membrane. The macrophages expressed all the macrophage pattern of antigen expression by these cells not associated antigens which were present on only has implications for synovial lining cell synovial lining cells and, in addition, expressed origin and development but also for function CD15a, CD25 (interleukin-2 receptor), CD34, and interaction of these cells with other inflam- and CD35 (C3b receptor), none of which was matory cells.
    [Show full text]
  • Macrophage Activation Markers, CD163 and CD206, in Acute-On-Chronic Liver Failure
    cells Review Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure Marlene Christina Nielsen 1 , Rasmus Hvidbjerg Gantzel 2 , Joan Clària 3,4 , Jonel Trebicka 3,5 , Holger Jon Møller 1 and Henning Grønbæk 2,* 1 Department of Clinical Biochemistry, Aarhus University Hospital, 8200 Aarhus N, Denmark; [email protected] (M.C.N.); [email protected] (H.J.M.) 2 Department of Hepatology & Gastroenterology, Aarhus University Hospital, 8200 Aarhus N, Denmark; [email protected] 3 European Foundation for the Study of Chronic Liver Failure (EF-CLIF), 08021 Barcelona, Spain; [email protected] (J.C.); [email protected] (J.T.) 4 Department of Biochemistry and Molecular Genetics, Hospital Clínic-IDIBAPS, 08036 Barcelona, Spain 5 Translational Hepatology, Department of Internal Medicine I, Goethe University Frankfurt, 60323 Frankfurt, Germany * Correspondence: [email protected]; Tel.: +45-21-67-92-81 Received: 1 April 2020; Accepted: 4 May 2020; Published: 9 May 2020 Abstract: Macrophages facilitate essential homeostatic functions e.g., endocytosis, phagocytosis, and signaling during inflammation, and express a variety of scavenger receptors including CD163 and CD206, which are upregulated in response to inflammation. In healthy individuals, soluble forms of CD163 and CD206 are constitutively shed from macrophages, however, during inflammation pathogen- and damage-associated stimuli induce this shedding. Activation of resident liver macrophages viz. Kupffer cells is part of the inflammatory cascade occurring in acute and chronic liver diseases. We here review the existing literature on sCD163 and sCD206 function and shedding, and potential as biomarkers in acute and chronic liver diseases with a particular focus on Acute-on-Chronic Liver Failure (ACLF).
    [Show full text]
  • Single-Cell RNA Sequencing Demonstrates the Molecular and Cellular Reprogramming of Metastatic Lung Adenocarcinoma
    ARTICLE https://doi.org/10.1038/s41467-020-16164-1 OPEN Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma Nayoung Kim 1,2,3,13, Hong Kwan Kim4,13, Kyungjong Lee 5,13, Yourae Hong 1,6, Jong Ho Cho4, Jung Won Choi7, Jung-Il Lee7, Yeon-Lim Suh8,BoMiKu9, Hye Hyeon Eum 1,2,3, Soyean Choi 1, Yoon-La Choi6,10,11, Je-Gun Joung1, Woong-Yang Park 1,2,6, Hyun Ae Jung12, Jong-Mu Sun12, Se-Hoon Lee12, ✉ ✉ Jin Seok Ahn12, Keunchil Park12, Myung-Ju Ahn 12 & Hae-Ock Lee 1,2,3,6 1234567890():,; Advanced metastatic cancer poses utmost clinical challenges and may present molecular and cellular features distinct from an early-stage cancer. Herein, we present single-cell tran- scriptome profiling of metastatic lung adenocarcinoma, the most prevalent histological lung cancer type diagnosed at stage IV in over 40% of all cases. From 208,506 cells populating the normal tissues or early to metastatic stage cancer in 44 patients, we identify a cancer cell subtype deviating from the normal differentiation trajectory and dominating the metastatic stage. In all stages, the stromal and immune cell dynamics reveal ontological and functional changes that create a pro-tumoral and immunosuppressive microenvironment. Normal resident myeloid cell populations are gradually replaced with monocyte-derived macrophages and dendritic cells, along with T-cell exhaustion. This extensive single-cell analysis enhances our understanding of molecular and cellular dynamics in metastatic lung cancer and reveals potential diagnostic and therapeutic targets in cancer-microenvironment interactions. 1 Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Korea.
    [Show full text]
  • Interleukin-9 Regulates Macrophage Activation in the Progressive Multiple Sclerosis Brain
    Donninelli et al. Journal of Neuroinflammation (2020) 17:149 https://doi.org/10.1186/s12974-020-01770-z RESEARCH Open Access Interleukin-9 regulates macrophage activation in the progressive multiple sclerosis brain Gloria Donninelli1†, Inbar Saraf-Sinik1,2†, Valentina Mazziotti3, Alessia Capone1,4, Maria Grazia Grasso5, Luca Battistini1, Richard Reynolds6, Roberta Magliozzi3,6*† and Elisabetta Volpe1*† Abstract Background: Multiple sclerosis (MS) is an immune-mediated, chronic inflammatory, and demyelinating disease of the central nervous system (CNS). Several cytokines are thought to be involved in the regulation of MS pathogenesis. We recently identified interleukin (IL)-9 as a cytokine reducing inflammation and protecting from neurodegeneration in relapsing–remitting MS patients. However, the expression of IL-9 in CNS, and the mechanisms underlying the effect of IL-9 on CNS infiltrating immune cells have never been investigated. Methods: To address this question, we first analyzed the expression levels of IL-9 in post-mortem cerebrospinal fluid of MS patients and the in situ expression of IL-9 in post-mortem MS brain samples by immunohistochemistry. A complementary investigation focused on identifying which immune cells express IL-9 receptor (IL-9R) by flow cytometry, western blot, and immunohistochemistry. Finally, we explored the effect of IL-9 on IL-9-responsive cells, analyzing the induced signaling pathways and functional properties. Results: We found that macrophages, microglia, and CD4 T lymphocytes were the cells expressing the highest levels of IL-9 in the MS brain. Of the immune cells circulating in the blood, monocytes/macrophages were the most responsive to IL-9. We validated the expression of IL-9R by macrophages/microglia in post-mortem brain sections of MS patients.
    [Show full text]
  • Integrin-Linked Kinase Deficiency in Collecting Duct Principal Cell
    BASIC RESEARCH www.jasn.org Integrin-Linked Kinase Deficiency in Collecting Duct Principal Cell Promotes Necroptosis of Principal Cell and Contributes to Kidney Inflammation and Fibrosis Ming Huang,1,2 Shuai Zhu,1,2 Huihui Huang,2 Jinzhao He,1,2 Kenji Tsuji,2 William W. Jin,2 Dongping Xie,3 Onju Ham,2 Diane E. Capen,2 Weining Lu,4 Teodor G. Paunescu, 2 Baoxue Yang,1 and Hua A. Jenny Lu2 1Department of Pharmacology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China; 2Center for Systems Biology, Program in Membrane Biology, Division of Nephrology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; 3Department of Physiology, Tongji University School of Medicine, Shanghai, China; and 4Renal Section, Departments of Medicine, and Pathology & Laboratory Medicine, Boston University Medical Center, Boston, Massachusetts ABSTRACT Background Necroptosis is a newly discovered cell death pathway that plays a critical role in AKI. The involvement of integrin-linked kinase (ILK) in necroptosis has not been studied. BASIC RESEARCH Methods We performed experiments in mice with an Ilk deletion in collecting duct (CD) principal cells (PCs), and cultured tubular epithelial cells treated with an ILK inhibitor or ILK siRNA knockdown. Results Ilk deletion in CD PCs resulted in acute tubular injury and early mortality in mice. Progressive interstitial fibrosis and inflammation associated with the activation of the canonical TGF-b signaling cas- cade were detected in the kidneys of the mice lacking ILK in the CD PCs. In contrast to the minimal apoptosis detected in the animals’ injured CDs, widespread necroptosis was present in ILK-deficient PCs, characterized by cell swelling, deformed mitochondria, and rupture of plasma membrane.
    [Show full text]
  • FULLTEXT01.Pdf
    http://www.diva-portal.org This is the published version of a paper published in International Journal of Oncology. Citation for the original published paper (version of record): Lindsten, T., Hedbrant, A., Ramberg, A., Wijkander, J., Solterbeck, A. et al. (2017) Effect of macrophages on breast cancer cell proliferation, and on expression of hormone receptors, uPAR and HER-2 International Journal of Oncology, 51(1): 104-114 https://doi.org/10.3892/ijo.2017.3996 Access to the published version may require subscription. N.B. When citing this work, cite the original published paper. © Lindsten et al. This is an open access article distributed under the terms of Creative Commons Attribution License. Permanent link to this version: http://urn.kb.se/resolve?urn=urn:nbn:se:kau:diva-65678 104 INTERNATIONAL JOURNAL OF ONCOLOGY 51: 104-114, 2017 Effect of macrophages on breast cancer cell proliferation, and on expression of hormone receptors, uPAR and HER-2 THERÉSE LINDSTEN1, ALEXANDER HEDBRANT2, ANNA RAMBERG1,2, JONNy WIJKANDER3, ANJA Solterbeck1, Margareta ERIKSSON1,5, DICK DELBRO2 and ANN ERLANDSSON4,5 1Department of Clinical Pathology and Cytology, Central Hospital Karlstad, SE-651 88 Karlstad; 2School of Medical Sciences, Örebro University, SE-702 81 Örebro; Departments of 3Health Sciences, 4Environmental and Life Sciences/Biology, Karlstad University, SE-651 88 Karlstad; 5Department of Urology, Faculty of Medicine and Health, Örebro University, Örebro University Hospital, SE-701 82 Örebro, Sweden Received February 13, 2017; Accepted March 27, 2017 DOI: 10.3892/ijo.2017.3996 Abstract. Malignant tumors, including breast cancers, capability to decrease the tumor cell expression of ERα and PR are frequently infiltrated with innate immune cells and in vitro.
    [Show full text]
  • BMP4 Induces M2 Macrophage Polarization and Favors Tumor Progression in Bladder Cancer Víctor G
    Published OnlineFirst September 19, 2017; DOI: 10.1158/1078-0432.CCR-17-1004 Biology of Human Tumors Clinical Cancer Research BMP4 Induces M2 Macrophage Polarization and Favors Tumor Progression in Bladder Cancer Víctor G. Martínez1, Carolina Rubio2,3,Monica Martínez-Fernandez 2,3, Cristina Segovia2,3, Fernando Lopez-Calder on 2, Marina I. Garín4, Alicia Teijeira2, Ester Munera-Maravilla2,5, Alberto Varas1, Rosa Sacedon 1,Felix Guerrero5, Felipe Villacampa3,5, Federico de la Rosa3,5, Daniel Castellano2,6, Eduardo Lopez-Collazo 7,8, Jesus M. Paramio2,3,5, Angeles Vicente1, and Marta Duenas~ 2,3,5 Abstract Purpose: Bladder cancer is a current clinical and social prob- showed that both recombinant BMP4 and BMP4-containing lem. At diagnosis, most patients present with nonmuscle-invasive conditioned media from bladder cancer cell lines favored mono- tumors, characterized by a high recurrence rate, which could cyte/macrophage polarization toward M2 phenotype macro- progress to muscle-invasive disease and metastasis. Bone mor- phages, as shown by the expression and secretion of IL10. Using phogenetic protein (BMP)–dependent signaling arising from a series of human bladder cancer patient samples, we also stromal bladder tissue mediates urothelial homeostasis by pro- observed increased expression of BMP4 in advanced and undif- moting urothelial cell differentiation. However, the possible role ferentiated tumors in close correlation with epithelial–mesenchy- of BMP ligands in bladder cancer is still unclear. mal transition (EMT). However, the p-Smad 1,5,8 staining in Experimental Design: Tumor and normal tissue from 68 tumors showing EMT signs was reduced, due to the increased miR- patients with urothelial cancer were prospectively collected and 21 expression leading to reduced BMPR2 expression.
    [Show full text]